Xilio Therapeutics (XLO) Common Equity (2020 - 2026)
Xilio Therapeutics (XLO) posted Common Equity of $72.5 million for Q1 2026, up 105.67% sequentially from $35.3 million in Q4 2025, and up 577.99% YoY from $10.7 million in Q1 2025.
Xilio Therapeutics (XLO) Common Equity (2020 - 2026) Analysis & Trends
Xilio Therapeutics has reported Common Equity for 7 years, with the latest figure at $72.5 million in Q1 2026.
- Quarterly Common Equity rose 577.99% year-over-year to $72.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $72.5 million (up 577.99% YoY) and the FY2025 annual result came in at $35.3 million, up 100.44% from the prior year.
- Common Equity grew to $72.5 million in Q1 2026 per XLO's latest filing, from $35.3 million in the prior quarter.
- Over five years, Common Equity peaked at $166.1 million in Q1 2022 and troughed at -$8.1 million in Q3 2025.
- A 5-year average of $58.8 million and a median of $36.8 million in 2023 frame the typical range for Common Equity.
- The sharpest annual moves came in 2025 and 2026: Common Equity sank 138.6% in 2025, then jumped 577.99% in 2026.
- Over 5 years, Common Equity stood at $105.6 million in 2022, then tumbled by 65.14% to $36.8 million in 2023, then plunged by 52.21% to $17.6 million in 2024, then surged by 100.44% to $35.3 million in 2025, then jumped by 105.67% to $72.5 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $72.5 million, $35.3 million, and -$8.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | Xilio Therapeutics | 177.75 Mn | 41.71 Mn | - | 72.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 72.26 Mn |
| Mar 31, 2026 | 72.55 Mn |
| Dec 31, 2025 | 35.27 Mn |
| Sep 30, 2025 | -8.10 Mn |
| Jun 30, 2025 | 7.07 Mn |
| Mar 31, 2025 | 10.70 Mn |
| Dec 31, 2024 | 17.60 Mn |
| Sep 30, 2024 | 20.97 Mn |
| Jun 30, 2024 | 33.42 Mn |
| Mar 31, 2024 | 25.77 Mn |
| Dec 31, 2023 | 36.83 Mn |
| Sep 30, 2023 | 52.50 Mn |
| Jun 30, 2023 | 67.38 Mn |
| Mar 31, 2023 | 84.79 Mn |
| Dec 31, 2022 | 105.65 Mn |
| Sep 30, 2022 | 126.30 Mn |
| Jun 30, 2022 | 144.22 Mn |
| Mar 31, 2022 | 166.12 Mn |
| Dec 31, 2021 | 185.43 Mn |
| Sep 30, 2021 | -136.46 Mn |